MedCity News July 14, 2024
RNA therapies developer miRecule is partnered with Sanofi on the development of a treatment for facioscapulohumeral muscular dystrophy, or FSHD. MiRecule, winner in the biopharma track of MedCity News’s Pitch Perfect startup competition, is now pursuing a Series A round of financing.
For biotech companies with platform technologies, one common goal is finding a big pharmaceutical partner interested in jumping onto that platform sooner or later. For miRecule, the collaboration came sooner. Within four years of its formation and still preclinical, the startup found itself working with Sanofi to develop an RNA therapy for a rare muscle disorder.
The disease, facioscapulohumeral muscular dystrophy (FSHD), is the second most common type of muscular dystrophy behind Duchenne muscular dystrophy. But unlike Duchenne,...
Today's Sponsors
Today's Sponsor